The high density and incidence of Y1 receptors in invasive and metastatic breast cancers, also expressing Y2 but not Y4 and Y5 receptors, make these neoplasms important targets for diagnosis and therapy with NPY-related drugs [8]. Here, NPY is linked to breast cancer.